155 related articles for article (PubMed ID: 29502190)
1. Biomolecular analysis of matrix proteoglycans as biomarkers in non small cell lung cancer.
Rangel MP; de Sá VK; Prieto T; Martins JRM; Olivieri ER; Carraro D; Takagaki T; Capelozzi VL
Glycoconj J; 2018 Apr; 35(2):233-242. PubMed ID: 29502190
[TBL] [Abstract][Full Text] [Related]
2. Matrix glycosaminoglycans in the growth phase of fibroblasts: more of the story in wound healing.
Kosir MA; Quinn CC; Wang W; Tromp G
J Surg Res; 2000 Jul; 92(1):45-52. PubMed ID: 10864481
[TBL] [Abstract][Full Text] [Related]
3. Proteoglycans as potential microenvironmental biomarkers for colon cancer.
Suhovskih AV; Aidagulova SV; Kashuba VI; Grigorieva EV
Cell Tissue Res; 2015 Sep; 361(3):833-44. PubMed ID: 25715761
[TBL] [Abstract][Full Text] [Related]
4. Heparan sulfate proteoglycan expression in human lung-cancer cells.
Nackaerts K; Verbeken E; Deneffe G; Vanderschueren B; Demedts M; David G
Int J Cancer; 1997 Jun; 74(3):335-45. PubMed ID: 9221815
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans and glycolipids as potential biomarkers in lung cancer.
Li G; Li L; Joo EJ; Son JW; Kim YJ; Kang JK; Lee KB; Zhang F; Linhardt RJ
Glycoconj J; 2017 Oct; 34(5):661-669. PubMed ID: 28822024
[TBL] [Abstract][Full Text] [Related]
6. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin.
Tsara ME; Theocharis AD; Theocharis DA
Anticancer Res; 2002; 22(5):2893-8. PubMed ID: 12530013
[TBL] [Abstract][Full Text] [Related]
7. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease.
Snow AD; Kinsella MG; Parks E; Sekiguchi RT; Miller JD; Kimata K; Wight TN
Arch Biochem Biophys; 1995 Jun; 320(1):84-95. PubMed ID: 7793988
[TBL] [Abstract][Full Text] [Related]
8. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
9. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation.
Sekiguchi RT; Potter-Perigo S; Braun K; Miller J; Ngo C; Fukuchi K; Wight TN; Kimata K; Snow AD
J Neurosci Res; 1994 Aug; 38(6):670-86. PubMed ID: 7807583
[TBL] [Abstract][Full Text] [Related]
10. Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma.
Skandalis SS; Theocharis AD; Theocharis DA; Papadas T; Vynios DH; Papageorgakopoulou N
Biochim Biophys Acta; 2004 Jun; 1689(2):152-61. PubMed ID: 15196596
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
12. Expression of heparan sulphate and small dermatan/chondroitin sulphate proteoglycans in chronically inflamed human periodontium.
Oksala O; Haapasalmi K; Häkkinen L; Uitto VJ; Larjava H
J Dent Res; 1997 Jun; 76(6):1250-9. PubMed ID: 9168858
[TBL] [Abstract][Full Text] [Related]
13. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes.
Makatsori E; Lamari FN; Theocharis AD; Anagnostides S; Hjerpe A; Tsegenidis T; Karamanos NK
Anticancer Res; 2003; 23(4):3303-9. PubMed ID: 12926067
[TBL] [Abstract][Full Text] [Related]
14. Proteoglycan expression patterns in human hair follicle.
Malgouries S; Thibaut S; Bernard BA
Br J Dermatol; 2008 Feb; 158(2):234-42. PubMed ID: 18067481
[TBL] [Abstract][Full Text] [Related]
15. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
16. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
17. Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.
Farnedi A; Rossi S; Bertani N; Gulli M; Silini EM; Mucignat MT; Poli T; Sesenna E; Lanfranco D; Montebugnoli L; Leonardi E; Marchetti C; Cocchi R; Ambrosini-Spaltro A; Foschini MP; Perris R
BMC Cancer; 2015 May; 15():352. PubMed ID: 25935541
[TBL] [Abstract][Full Text] [Related]
18. The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer.
Skandalis SS; Kletsas D; Kyriakopoulou D; Stavropoulos M; Theocharis DA
Biochim Biophys Acta; 2006 Aug; 1760(8):1217-25. PubMed ID: 16730906
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
20. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
